TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)

By SquaredTown on July 25, 2025

Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA European Commission decision expected by Q4 2025 STOCKHOLM, July 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and...

Read More